Loading news...
WHITE BEAR LAKE, Minn., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health company pioneering fully implanted hearing solutions, today announced that management will participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026.
Envoy Medical (NASDAQ: COCH - Get Free Report) and Sensus Healthcare (NASDAQ: SRTS - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Risk and Volatility Envoy Medical has a
NeuroPace (NASDAQ: NPCE - Get Free Report) and Envoy Medical (NASDAQ: COCH - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership. Insider and Institutional Ownership 78.8% of NeuroPace shares
Enrollment momentum accelerates as Company advances toward full enrollment White Bear Lake, Minnesota--(Newsfile Corp. - December 18, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that its pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant has achieved yet another milestone by reaching the midway point of the study's full enrollment target. Despite holiday scheduling and year-end operating room constraints, enrollment is progressing at a steady pace.
White Bear Lake, Minnesota--(Newsfile Corp. - December 16, 2025) - Envoy Medical Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"),
Momentum continues to build for Company as series of clinical milestones are met, design choices cement differentiation from competition, and timeline comes into focus White Bear Lake, Minnesota--(Newsfile Corp. - December 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the completion of the first set of activations in the final stage of the pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant. These activations were performed at Shohet Ear Associates in Seal Beach, California and the Center for Neurosciences Ear and Hearing Center in Tucson, Arizona, two of the seven investigational sites involved in the study.
Event to Take Place December 11th at 4:30 P.M. ET White Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:30 P.M.
Envoy Medical, Inc. (COCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New Patent Adds to Company's Growing Portfolio of Intellectual Property Focused on Fully Implanted Hearing Devices White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens the Company's intellectual property portfolio, which includes an additional 45 issued foreign patents.
Patent adds to Envoy Medical's expanding intellectual property portfolio, reinforcing the Company's leadership in next generation cochlear implant innovation White Bear Lake, Minnesota--(Newsfile Corp. - November 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of U.S. Patent No. 12,465,754, granted by the United States Patent and Trademark Office (USPTO) on November 11, 2025.
Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.37 per share a year ago.
Transformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet, and further expanded its patent portfolio; In addition, subsequent to quarter end, the Company received FDA approval to expand its pivotal clinical trial to the final stage, restarted enrollment, and successfully raised additional capital White Bear Lake, Minnesota--(Newsfile Corp. - November 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced its corporate and financial results for the third quarter ended September 30, 2025, as well as other subsequent events. Corporate Highlights for Third Quarter 2025: Extinguished over $32 Million in Debt, Strengthening Balance Sheet Advanced Commercialization Planning as FDA Clinical Trial Remains On Track Expanded Patent Portfolio by Securing Additional European Patent Secured Four New Global Patents Successfully Reached Three-Month Follow-Up Milestone in Clinical Trial Secured an Additional Three New Patents Further Expanded Patent Portfolio with New Issuances in the United States Subsequent to Third Quarter 2025 End Received FDA Approval to Expand Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data Announced Closing of Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Marked three-year anniversary of first successful implantation of fully implanted cochlear implant Announced first three patients were enrolled in the final stage of pivotal clinical trial of the fully implanted investigational Acclaim® cochlear implant "The third quarter was transformational for Envoy Medical as we continue to position ourselves to capitalize on the opportunity ahead of us," said Brent Lucas, Chief Executive Officer of Envoy Medical, "We extinguished $32 million in debt without the issuance of new equity, substantially improving our balance sheet and eliminating the need to satisfy or service that debt in the future.
Envoy Medical, Inc. (COCH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rapid patient enrollment underscores strong market interest and reinforces commercialization opportunity for fully implanted cochlear implants White Bear Lake, Minnesota--(Newsfile Corp. - November 4, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the first three patients have been enrolled in the final stage of the Company's pivotal clinical trial of the full implanted Acclaim® cochlear implant. These initial surgeries in this final stage were performed by Dr. Abraham Jacob at the Center for Neurosciences Ear and Hearing Center in Tucson, Arizona and Dr. Jack Shohet at Shohet Ear Associates in Seal Beach, California, two of the seven investigational sites in the United States.
The Company looks to build on its recent momentum - receiving FDA approval to expand its pivotal clinical trial into the second and final stage White Bear Lake, Minnesota--(Newsfile Corp. - October 29, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the three-year anniversary of the first patient receiving its breakthrough first fully implanted cochlear implant. On October 24, 2022, Craig Eggert became the first patient in the world to be implanted with Envoy Medical's new investigational fully implanted cochlear implant.
White Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the Nasdaq Hearings Panel (the "Panel) has granted the Company's request for continued listing on the Nasdaq Stock Market. In granting the extension, the Panel considered several key developments, including Envoy Medical's recent equity capital raises and debt extinguishment, which combined together substantially increased the Company's stockholders' equity, and the FDA's recent approval of the Company's advancement to the final stage of the fully implanted Acclaim® cochlear implant clinical trial.
Envoy Medical, Inc. (COCH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
$4 million upfront with up to additional $12 million of potential aggregate gross proceeds upon the exercise in full of warrants White Bear Lake, Minnesota--(Newsfile Corp. - October 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,007,524 shares of its Class A common stock at a purchase price of $1.33 per share. In addition, in a concurrent private placement, Envoy Medical issued and sold unregistered warrants to purchase up to 9,022,572 shares of Class A common stock.
$4 million upfront with up to additional $12 million of potential aggregate gross proceeds upon the exercise in full of warrants White Bear Lake, Minnesota--(Newsfile Corp. - October 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 3,007,524 shares of its Class A common stock at a purchase price of $1.33 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Envoy Medical will issue and sell unregistered warrants to purchase up to 9,022,572 shares of Class A common stock.
The Company expects to complete full enrollment by early 2026 and is moving its timelines up three to six months, cutting its anticipated capital needs by $10-$15 million White Bear Lake, Minnesota--(Newsfile Corp. - October 7, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it received approval from the U.S. Food and Drug Administration (FDA) to expand the Company's pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage based on promising three-month data from the first 10 patients. The FDA's approval of the expansion request removes a previously uncertain timing variable and allows the Company to solidify its path toward regulatory approval.